{"organizations": [], "uuid": "fe5c655640fdb774b2a39cc8f5e19c30bae15532", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.wsj.com", "main_image": "http://si.wsj.net/public/resources/images/BN-KS397_1012li_G_20151012123503.jpg", "site_section": "http://www.wsj.com/news/markets", "section_title": "Stock Market &amp; Finance News - Wall Street Journal", "url": "http://www.wsj.com/articles/why-lillys-pipeline-worries-arent-over-1444671278", "country": "", "title": "Why Lilly’s Pipeline Worries Aren’t Over", "performance_score": 0, "site": "wsj.com", "participants_count": 1, "title_full": "Why Lilly’s Pipeline Worries Aren’t Over - WSJ", "spam_score": 0.0, "site_type": "news", "published": "2015-10-12T21:34:00.000+03:00", "replies_count": 0, "uuid": "fe5c655640fdb774b2a39cc8f5e19c30bae15532"}, "author": "Charley Grant", "url": "http://www.wsj.com/articles/why-lillys-pipeline-worries-arent-over-1444671278", "ord_in_thread": 0, "title": "Why Lilly’s Pipeline Worries Aren’t Over", "locations": [], "entities": {"persons": [], "locations": [], "organizations": []}, "highlightText": "", "language": "english", "persons": [], "text": "The failure of a major drug candidate has Eli Lilly’s pipeline looking a little less bountiful. That raises the stakes for its remaining programs.\nThe company’s investors were dealt a body blow on Monday morning when the company announced the termination of a Phase 3 trial for its experimental heart-disease treatment, evacetrapib. The study was discontinued for a lack of efficacy.\nIn some ways, the news shouldn’t have come as... To Read the Full Story, Subscribe or Sign In", "external_links": [], "published": "2015-10-12T21:34:00.000+03:00", "crawled": "2015-10-12T20:46:32.907+03:00", "highlightTitle": ""}